Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells.

Molecular and cellular endocrinology - 15 Apr 2024

Cipolletti Manuela, Acconcia Filippo

Abstract excerpt

PURPOSE: Metabolic reprogramming in breast cancer (BC) subtypes offers potential personalized treatment targets. Estrogen receptor α (ERα)-positive BC patients undergoing endocrine therapy (ET) can develop ET-resistant metastatic disease. Specific mutations, like Y537S in ERα, drive uncontrolled cell proliferation. Targeting mutant receptor levels shows promise for inhibiting growth in metastatic BC expressing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cell Proliferation
Share to Estrogen Receptor alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Recurrence, Local

Source

Identifiers

PMID: 38266771
DOI: 10.1016/j.mce.2024.112160

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells.PMID 38266771Read ↗

PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cellsSemantic proximity Read ↗

L370F and Y537S ESR1 mutations determine distinct endocrine therapy sensitivities and metabolic vulnerabilities that define new opportunities for synergistic therapeutic combinationsSemantic proximity Read ↗

Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast CancerSemantic proximity Read ↗

Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer.Semantic proximity Read ↗

FBXW7 mutations reprogram glucose metabolism by activating the ETV6-GLUT1 axis.Semantic proximity Read ↗

Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer CellsSemantic proximity Read ↗

Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling.Semantic proximity Read ↗

Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.Semantic proximity Read ↗

Modification of ERα by UFM1 Increases Its Stability and Transactivity for Breast Cancer DevelopmentSemantic proximity Read ↗

ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferationSemantic proximity Read ↗

Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects.Semantic proximity Read ↗

Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.